Trial Profile
Ethinylestradiol-levonorgestrel versus spironolactone-pioglitazone-metformin (SPIOMET) for adolescent girls with hyperinsulinemic androgen excess: effects on hepatic and visceral fat and on insulin sensitivity
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2023
Price :
$35
*
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Spironolactone (Primary)
- Indications Hyperinsulinaemia; Polycystic ovary syndrome
- Focus Pharmacodynamics
- Acronyms OC vs SPIOMET
- 08 Oct 2023 Results of post hoc pooled analysis assessing the pooled pre-treatment data of 65 adolescent girls with PCOS-without-obesity in three reported studies (ISRCTN 45546616; 29234515; 11062950) and the results of 24 adolescent girls with PCOS-without-obesity, who received pioglitazone (7.5 mg/d for 1 year) as part of a randomized combination treatment (with spironolactone and metformin) in two reported studies (29234515; 11062950), published in the Journal of Endocrinological Investigation.
- 11 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2015 Planned End Date changed from 10 Dec 2016 to 30 Dec 2018 as per ISRCTN: Current Controlled Trials record.